First Manhattan’s Galectin Therapeutics GALT Stock Holding History

First Manhattan’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,667	Closed	-$4K	–	1449
2017 Q2	$4K	Hold	1,667	–	–	﹤0.01%	1263
2017 Q1	$3K	Hold	1,667	–	–	﹤0.01%	1307
2016 Q4	$1K	Hold	1,667	–	–	﹤0.01%	1329
2016 Q3	$1K	Hold	1,667	–	–	﹤0.01%	1351
2016 Q2	$2K	Hold	1,667	–	–	﹤0.01%	1398
2016 Q1	$2K	Hold	1,667	–	–	﹤0.01%	1321
2015 Q4	$2K	Hold	1,667	–	–	﹤0.01%	1339
2015 Q3	$3K	Hold	1,667	–	–	﹤0.01%	1306
2015 Q2	$4K	Hold	1,667	–	–	﹤0.01%	1314
2015 Q1	$5K	Hold	1,667	–	–	﹤0.01%	1301
2014 Q4	$5K	Hold	1,667	–	–	﹤0.01%	1324
2014 Q3	$8K	Hold	1,667	–	–	﹤0.01%	1237
2014 Q2	$23K	Hold	1,667	–	–	﹤0.01%	1074
2014 Q1	$25K	Hold	1,667	–	–	﹤0.01%	1058
2013 Q4	$13K	Hold	1,667	–	–	﹤0.01%	1125
2013 Q3	$16K	Hold	1,667	–	–	﹤0.01%	1100
2013 Q2	$8K	Buy	+1,667	New	+$6.83K	﹤0.01%	1181

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan's GALT Position: Q3 2017 in Review

First Manhattan sold out of Galectin Therapeutics (GALT) in Q3 2017, closing a stake of 1,667 shares — an estimated $4K sold.

First Manhattan first reported a position in GALT in Q2 2013 and held it in 17 quarters. The position peaked at $25K in Q1 2014. 49 funds tracked by Wall St. Rank hold GALT as of Q3 2017.

First Manhattan reported no remaining Galectin Therapeutics position as of Q3 2017 after selling out during the quarter.
First Manhattan sold 1,667 Galectin Therapeutics shares in Q3 2017, an estimated $4K.
First Manhattan first reported a position in Galectin Therapeutics in Q2 2013 and held it in 17 quarters.
First Manhattan's Galectin Therapeutics position peaked at $25K in Q1 2014.
49 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2017.

Based on First Manhattan's 13F filing for Q3 2017, filed 25 Oct 2017.